OXYVIN-DF

Nasal spray 0.025%, 0.05%, 10 ml.

Respiratory system. Nasal preparations. Anticongestants and other nasal medications for topical use. Simple sympathomimetics. Oxymetazoline.

ATC code R01AA05

• acute, allergic vasomotor rhinitis;
• rhinosinusitis;
• eustachyitis associated with rhinitis;
• elimination of nasal cavity mucous membrane edema before diagnostic procedures.

• hypersensitivity to the components of the product;
• atrophic rhinitis;
• pronounced atherosclerosis;
• chronic heart failure;
• arrhythmias;
• arterial hypertension;
• chronic renal failure;
• prostatic hyperplasia;
• concomitant use of monoamine oxidase inhibitors and a period of up to 14 days after the end of their use;
• diabetes mellitus;
• thyrotoxicosis, hyperthyroidism;
• closed angle glaucoma;
• severe eye diseases;
• pheochromacytoma;
• porphyria
• children under 1 year of age (for Oxyvin-DF® 0.025%);
• children under 6 years of age (for Oxyvin-DF 0.05%).

Intranasally.

In order to inject correctly, remove the protective cap, gently press the plastic spray tip 1 – 2 times so that the solution enters the atomizer and sprays. Then the nozzle of the bottle should be placed in the nasal passage, quickly and sharply press once on the atomizer and take out the nozzle without unclenching the atomizer.

• 0.025% nasal spray for children of 1 to 6 years of age: 1 injection into each nasal passage 2-3 times a day.
• 0.05% nasal spray for children over 6 years of age: 1 injection into each nasal passage 2-3 times a day.

The course of treatment is not more than 5-7 days.

Common:

• burning and dryness of the nasal mucosa;
• dry mouth and throat;
• sneezing.

Uncommon:

• dizziness, headache;
• insomnia;
• tiredness (fatigue);
• nausea;
• swelling and edema of the mucous membrane (nasal congestion);
• reactive hyperemia;
• atrophy of the mucous membrane;
• allergic reactions (Quincke’s edema, urticaria, itching).

Very rare:

• increased pulse rate;
• arterial hypertension;
• tachycardia;
• tachyphylaxis.

Symptoms: constriction of the pupils, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, collapse, cardiac depression, arterial hypertension, pulmonary edema, respiratory distress.

Treatment: immediately administer activated charcoal (absorbent), sodium sulfate (laxative) or gastric lavage. Non-selective alpha-adrenoblockers (phentolamine 5 mg in saline (physiological) solution slowly v/v or 100 mg orally) are prescribed to decrease blood pressure.

Use of the product during pregnancy and lactation is possible only when the estimated benefit to the mother exceeds the potential risk to the child and fetus.

For children

• 1 to 6 years of age – Oxyvin-DF® 0.025%.
• over 6 years of age – Oxyvin-DF® 0.05%.

Prolonged use of Oxyvin-DF® should be avoided as it may lead to a decrease of its therapeutic effect.

You should not independently exceed the recommended doses and use the product for more than 5-7 days.

Use with caution in coronary heart disease (CHD).

10 ml of the product in plastic brown bottles with a pump dispensing device, including an aluminum flap with a dip tube and a plastic spray tip with a protective cap. Each bottle has a label. One bottle is with instruction for use in the state and Russian language are placed in a carton pack.

Store in a place protected from light, at a temperature below 25⁰С.

Keep out of the reach of children.

3 years

“DOSFARM” LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan, tel.: (727) 253-03-88.

“DOSFARM” LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan.

Name, address, contact information of the organization accepting claims (proposals) against quality of products from consumers in the territory of the Republic of Kazakhstan, which is responsible for post-authorization safety surveillance of the medicine:

“DOSFARM” LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan,

Tel./Fax: (727) 253-07-07, 253-03-88, e-mail: dosfarm@dosfarm.kz